Home » Stocks » Acura Pharmaceuticals

Acura Pharmaceuticals, Inc. (ACUR)

Stock Price: $0.260 USD -0.010 (-3.70%)
Updated Aug 7, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 5.63M
Revenue (ttm) 3.68M
Net Income (ttm) -3.58M
Shares Out 21.65M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $0.260
Previous Close $0.270
Change ($) -0.010
Change (%) -3.70%
Day's Open 0.295
Day's Range 0.260 - 0.295
Day's Volume 6,302
52-Week Range 0.120 - 0.630

More Stats

Market Cap 5.63M
Enterprise Value 10.42M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 21.65M
Float 7.49M
EPS (basic) -0.15
EPS (diluted) -0.12
FCF / Share 0.00
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 2.27%
Payout Ratio n/a
Shares Short 89,846
Short Ratio 0.73
Short % of Float 1.20%
Beta 1.12
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 43.98
PS Ratio 1.53
PB Ratio n/a
Revenue 3.68M
Operating Income -525,000
Net Income -3.58M
Free Cash Flow 128,000
Net Cash -4.79M
Net Cash / Share -0.22
Gross Margin 31.30%
Operating Margin -14.26%
Profit Margin -97.30%
FCF Margin 3.48%
ROA 4.53%
ROE n/a
ROIC -74.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$6.00*
Low
6.00
Current: $0.260
High
6.00
Target: 6.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2.660.412.974.468.590.750.12-20.473.31
Revenue Growth548.05%-86.18%-33.56%-48.01%1043.41%510.57%--518.12%-
Gross Profit2.660.412.844.017.930.32-0.24-20.473.31
Operating Income-0.73-3.92-5.23-6.56-4.00-12.20-14.09-9.7410.53-12.72
Net Income-3.77-3.84-5.68-7.39-4.99-13.21-13.90-9.6710.39-12.71
Shares Outstanding26.7221.1515.9011.8710.809.789.559.509.509.41
Earnings Per Share-0.14-0.18-0.36-0.62-0.46-1.35-1.45-1.001.10-1.35
Operating Cash Flow-0.62-3.91-4.51-5.56-3.69-11.04-13.68-7.0412.31-6.48
Capital Expenditures--0.31-0.08-0.20-2.14-0.02-0.15-0.13-0.04
Free Cash Flow-0.62-3.91-4.20-5.64-3.89-13.18-13.70-7.1912.18-6.52
Cash & Equivalents0.860.092.225.1813.3212.1026.0727.4235.6924.05
Total Debt6.004.222.695.367.759.569.60---
Net Cash / Debt-5.14-4.13-0.47-0.175.572.5416.4727.4235.6924.05
Assets2.562.154.608.2116.9616.0328.6329.0637.1725.49
Liabilities7.305.774.637.039.0610.9810.711.430.531.15
Book Value-4.74-3.62-0.031.187.905.0517.9227.6336.6424.34
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Acura Pharmaceuticals, Inc.
Country United States
Employees 12
CEO Robert B. Jones

Stock Information

Ticker Symbol ACUR
Stock Exchange US OTC
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier OTCMKTS: ACUR

Description

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.